sanyang xuedai

a traditional Chinese antitumor drug consisting of fructus amomi, sanguis draconis, Angelicae sinensis, rhizoma glycyrrhizae, poria cocos, ginger, rhizoma dioscoreae, and rhizoma notoginseng; enhances sensitivity of lung cancer cells to radiation

Also Known As:

SYKT

Networked: 3 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Plant Preparations: 622
    - Plant Extracts: 3916
      - Chinese Herbal Drugs: 73
        sanyang xuedai: 3
Pharmaceutical Preparations
- Chinese Herbal Drugs: 73
  - sanyang xuedai: 3

Experts

1.	Chen, Ting: 3 articles (06/2018 - 04/2017)
2.	Li, Wenhui: 2 articles (06/2018 - 01/2018)
3.	Wang, Li: 2 articles (06/2018 - 04/2017)
4.	Hou, Yu: 1 article (06/2018)
5.	Li, Lan: 1 article (06/2018)
6.	Liu, Zhijie: 1 article (06/2018)
7.	Xia, Yaoxiong: 1 article (06/2018)
8.	Zeng, Yueqin: 1 article (06/2018)
9.	Deng, Zhiyong: 1 article (01/2018)
10.	Shen, Hongmei: 1 article (01/2018)

Related Diseases

1.	Cardiotoxicity 04/01/2017 - "The present study investigated whether SYKT can confer protection against DOX‑induced myelosuppression and cardiotoxicity, and explored the potential mechanism involved. " 01/01/2018 - "This study aimed at investigating whether SYKT alleviated DOX-induced cardiotoxicity by inhibiting ROS-mediated apoptosis and elucidating the role of ROS-mediated p53 and MAPK signal pathways' activation in this process. " 04/01/2017 - "The present study indicated that SYKT may counteract DOX‑induced myelosuppression and cardiotoxicity through inhibiting ROS‑mediated apoptosis. " 01/01/2018 - "Our results indicated that SYKT alleviated DOX-induced cardiotoxicity by inhibiting p53 and MAPK signal pathways' activation-mediated apoptosis, and it might serve as a potential therapeutic agent for DOX-induced cardiotoxicity." 04/01/2017 - "A herbal formula, SYKT, reverses doxorubicin‑induced myelosuppression and cardiotoxicity by inhibiting ROS‑mediated apoptosis."
2.	Neoplasms (Cancer) 04/01/2017 - "Notably, SYKT did not interfere with the effects of DOX on tumor volume or the induction of tumor cell apoptosis in tumor‑bearing mice. "
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/01/2018 - "In this research, we aimed at finding out how San Yang Xue Dai (SYKT) promotes the radiosensitivity of non-small cell lung cancer (NSCLC) cell line NCI-H460. " 06/01/2018 - "Sanyang Xuedai enhances the radiosensitivity of human non-small cell lung cancer cells via increasing iNOS/NO production."

Related Drugs and Biologics

1.	sanyang xuedai
2.	Doxorubicin (Adriamycin)
3.	Antioxidants